HomeCompareZYNE vs MO

ZYNE vs MO: Dividend Comparison 2026

ZYNE yields 153.85% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZYNE wins by $28.35M in total portfolio value
10 years
ZYNE
ZYNE
● Live price
153.85%
Share price
$1.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.43M
Annual income
$12,477,713.99
Full ZYNE calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — ZYNE vs MO

📍 ZYNE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZYNEMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZYNE + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZYNE pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZYNE
Annual income on $10K today (after 15% tax)
$13,076.92/yr
After 10yr DRIP, annual income (after tax)
$10,606,056.89/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, ZYNE beats the other by $10,580,421.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZYNE + MO for your $10,000?

ZYNE: 50%MO: 50%
100% MO50/50100% ZYNE
Portfolio after 10yr
$14.26M
Annual income
$6,253,936.57/yr
Blended yield
43.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ZYNE
Analyst Ratings
3
Buy
6
Hold
Consensus: Hold
Altman Z
-8.9
Piotroski
2/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZYNE buys
0
MO buys
0
No recent congressional trades found for ZYNE or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZYNEMO
Forward yield153.85%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$28.43M$80.1K
Annual income after 10y$12,477,713.99$30,159.17
Total dividends collected$26.36M$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: ZYNE vs MO ($10,000, DRIP)

YearZYNE PortfolioZYNE Income/yrMO PortfolioMO Income/yrGap
1← crossover$26,085$15,384.62$10,570$780.30+$15.5KZYNE
2$65,415$37,504.84$11,381$1,032.90+$54.0KZYNE
3$157,896$87,902.04$12,535$1,392.73+$145.4KZYNE
4$367,242$198,293.18$14,193$1,920.91+$353.0KZYNE
5$823,976$431,026.91$16,618$2,723.68+$807.4KZYNE
6$1,785,476$903,821.11$20,263$3,993.80+$1.77MZYNE
7$3,740,825$1,830,365.98$25,936$6,098.36+$3.71MZYNE
8$7,586,679$3,583,996.66$35,166$9,775.01+$7.55MZYNE
9$14,910,849$6,793,102.33$51,026$16,597.78+$14.86MZYNE
10$28,432,323$12,477,713.99$80,113$30,159.17+$28.35MZYNE

ZYNE vs MO: Complete Analysis 2026

ZYNEStock

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Full ZYNE Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this ZYNE vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZYNE vs SCHDZYNE vs JEPIZYNE vs OZYNE vs KOZYNE vs MAINZYNE vs PMZYNE vs BTIZYNE vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.